Drug · CHEMBL997
IBANDRONIC ACID
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. IBANDRONIC ACID. Drugs and targets, record CHEMBL997. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL997
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 10 of its 17 diseases, from ATC, EMA Human Drugs and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| FDPS | Farnesyl pyrophosphate synthase | Farnesyl diphosphate synthase inhibitor | INHIBITOR | https://conductscience.org/library/genes/2224 |
Source ChEMBL
Diseases17
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 17Source Open Targets
See all 17 diseasesTrials75
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00127205 | S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. | Phase 3 | 6,097 | 2019-08-28 | ibandronate | Its name | ClinicalTrials.gov |
| NCT00048061 | MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis | Phase 3 | 1,609 | 2016-05-30 | ibandronate | Its name | ClinicalTrials.gov |
| NCT00048074 | DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis | Phase 3 | 1,395 | 2016-02-03 | ibandronate | Its name | ClinicalTrials.gov |
| NCT00936897 | A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates | Phase 3 | 833 | 2012-11-29 | ibandronate | Its name | ClinicalTrials.gov |
| NCT00503113 | A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease. | Phase 4 | 801 | 2011-06-17 | ibandronate | Its name | ClinicalTrials.gov |
| NCT00551174 | A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment | Phase 4 | 781 | 2011-05-30 | ibandronate | Its name | ClinicalTrials.gov |
| NCT00081653 | A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva | Phase 4 | 719 | 2009-07-21 | ibandronate | Its name | ClinicalTrials.gov |
| NCT00545363 | A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP) | Phase 4 | 716 | 2016-10-24 | ibandronate | Its name | ClinicalTrials.gov |
| NCT00545779 | BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy. | Phase 3 | 677 | 2016-10-28 | ibandronate | Its name | ClinicalTrials.gov |
| NCT00405392 | Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis | Phase 4 | 365 | 2018-06-06 | ibandronate | Its name | ClinicalTrials.gov |
1 to 10 of 75
See all 75 trialsComparisons in its trials15
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ibandronate 150 mg PO QM vs Denosumab 60 mg SC Q6M: serious adverse events | 22 of 410 | 39 of 411 | 821 | NCT00936897 | Trial comparisons |
| 2 mg Ibandronate q2mo vs 3 mg Ibandronate q3mo: serious adverse events | 90 of 381 | 84 of 400 | 781 | NCT00551174 | Trial comparisons |
| Ibandronate 100 mg vs Ibandronate 150 mg: serious adverse events | 68 of 358 | 70 of 361 | 719 | NCT00081653 | Trial comparisons |
| BMF Participants vs No BMF Participants: serious adverse events | 8 of 354 | 5 of 357 | 711 | NCT00545363 | Trial comparisons |
| Ibandronate 150 mg Once Monthly vs Risedronate 35 mg Once Weekly: deaths from any cause | 0 of 336 | 0 of 334 | 670 | NCT00405392 | Trial comparisons |
| Ibandronate 150 mg Once Monthly vs Risedronate 35 mg Once Weekly: serious adverse events | 6 of 336 | 4 of 334 | 670 | NCT00405392 | Trial comparisons |
| Ibandronate vs Risedronate: serious adverse events | 5 of 327 | 3 of 327 | 654 | NCT00377234 | Trial comparisons |
| Ibandronate (IBN) 150 mg Monthly vs Placebo: serious adverse events | 3 of 77 | 1 of 83 | 160 | NCT00129623 | Trial comparisons |
| Ibandronate vs Placebo: serious adverse events | 10 of 70 | 6 of 70 | 140 | NCT00545051 | Trial comparisons |
| Ibandronate vs Placebo: serious adverse events | 7 of 86 | 6 of 47 | 133 | NCT00397839 | Trial comparisons |
1 to 10 of 15
See all 15 comparisons in its trialsPapers from its trials42
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL997
GET https://conductscience.org/api/drugs/v1/CHEMBL997/trials?page=2